Peanut Allergy Clinical Trial
Official title:
Early Peanut Introduction: Translation to Clinical Practice
The recent finding that early introduction of peanut can prevent ~70-90% of peanut allergy is a major step towards prevention of food allergy. However, because that finding was from a clinical trial in a very select population, there are several major questions that must be answered in order to implement these findings into clinical practice without causing more harm than good. These questions include who, if anyone, should be screened prior to early introduction for peanut allergy, how this screening should be done, and what quantity of peanut ingestion is needed to prevent peanut allergy. The goal of this project is to answer these critical questions so that the potential of these recent findings can be realized. To that end, 400 infants at high-risk of peanut allergy will be enrolled. These infants will be given a peanut skin prick test, peanut food challenge and have blood drawn for measurement of peanut IgE, and then will be followed for assessment of peanut consumption and development of peanut allergy until 3 years of age.
400 infants aged 4-11 months from three high risk groups will be enrolled in a prospective observational study. All subjects will have a baseline research clinic visit, where they will be given a peanut skin prick test, peanut food challenge and have blood drawn for measurement of peanut immunoglobulin E (IgE). Based on the baseline oral food challenge, the participants will be advised to begin introducing peanut following the current practice guidelines. Participants will then be followed until 30 months of age with two clinic visits and regular monitoring of peanut consumption. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05667610 -
Immune-supportive Diet and Gut Permeability in Allergic Children
|
N/A | |
| Recruiting |
NCT05440643 -
Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy
|
Phase 1 | |
| Terminated |
NCT03849079 -
Validation of the HYPONUT Product
|
N/A | |
| Completed |
NCT02979600 -
Clinical and Biological Efficacy of Peanut Oral Immunotherapy
|
N/A | |
| Completed |
NCT01955109 -
Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children
|
Phase 2 | |
| Completed |
NCT01950533 -
The Utility of Food-Specific IgE Measured With the IMMULITE 2000 Assay to Predict Symptomatic Food Allergy
|
||
| Recruiting |
NCT04415593 -
High and Low Dose Oral Peanut Immunotherapy - Comparison of Efficacy and Safety
|
N/A | |
| Active, not recruiting |
NCT04511494 -
Oral Immunotherapy for Young Children With Peanut Allergy - Small Children OIT
|
N/A | |
| Active, not recruiting |
NCT04887441 -
Allergology: Information, Data and Knowledge Organization
|
||
| Active, not recruiting |
NCT04881773 -
Oral Low Doses Tolerance INduction Study for Peanuts
|
||
| Completed |
NCT03682770 -
Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)
|
Phase 2 | |
| Terminated |
NCT03703791 -
Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents
|
Phase 3 | |
| Completed |
NCT02916446 -
Safety Study of Viaskin Peanut to Treat Peanut Allergy
|
Phase 3 | |
| Active, not recruiting |
NCT02402231 -
Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy
|
Phase 2 | |
| Completed |
NCT03337542 -
AR101 Real-World Open-Label Extension Study
|
Phase 3 | |
| Recruiting |
NCT05476497 -
Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects
|
Phase 1 | |
| Completed |
NCT03648320 -
The Grown Up Peanut Immunotherapy Study
|
N/A | |
| Completed |
NCT03292484 -
Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)
|
Phase 3 | |
| Completed |
NCT03852342 -
Reactive Doses and Times During Oral Food Challenge to Peanut
|
||
| Recruiting |
NCT05138757 -
Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy
|
Phase 1/Phase 2 |